A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Neurology, Neurology, ALS |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/19/2018 |
| Start Date: | June 21, 2018 |
| End Date: | February 2019 |
The causes of ALS are largely unknown. However, mitochondrial dysfunction, resulting in
impaired energy production, oxidative stress and apoptosis, may play a key role in ALS
progression. Triheptanoin can improve mitochondrial function and energy production and
therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron
loss and delayed the onset of weakness in a mutant SOD1 model of ALS. This pilot trial will
determine if Triheptanoin is safe tolerable, alters biomarkers of brain energy metabolism and
oxidative stress, and slows functional decline in people with ALS.
impaired energy production, oxidative stress and apoptosis, may play a key role in ALS
progression. Triheptanoin can improve mitochondrial function and energy production and
therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron
loss and delayed the onset of weakness in a mutant SOD1 model of ALS. This pilot trial will
determine if Triheptanoin is safe tolerable, alters biomarkers of brain energy metabolism and
oxidative stress, and slows functional decline in people with ALS.
This is an open label, prospective cohort study of 10 people with ALS (PALS) from the Duke
ALS Clinic. The first 5 enrolled PALS (Group 1) will receive standard ALS care for the first
month, then standard care plus Triheptanoin for the next 5 months. The next 5 enrolled PALS
(Group 2) will receive standard ALS care plus Triheptanoin for 6 months (Figure 1). All Group
1 and Group 2 PALS who complete this 6-month study will have an option for Triheptanoin
treatment extension for an additional 12 months. In addition to the PALS, there will also be
5 healthy controls enrolled (Group 3), people that do not have ALS or any other
neurodegenerative disease). These participants will not receive any treatment; the only
outcome measure they will complete is serum and urine biomarker testing at
screening/baseline, month 1 and month 6.
The rationale for delaying triheptanoin treatment in one group is to look for differences in
MR spectroscopy related to treatment at the 1 month time point. The target triheptanoin dose
for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable
and altered brain MR spectroscopy in patients with Huntington's Disease. Participants will
taper up to this dose as follows: start at 0.25g/kg/d for 1 week, then take 0.5g/kg/d for 1
week, then take 1g/kg/d and stay on this dose for the duration of the study. Triheptanoin
will be administered orally with food or by gastrostomy tube over 3 divided doses (breakfast,
lunch, and dinner). If at any point after week 1 a participant does not appear to be
tolerating their current dose, it will be reduced by 0.25g/kg/d. If they cannot tolerate the
starting dose of 0.25g/kg/d, the treatment will be discontinued. A dietician will make
contact with all participants every month, either in person or by telephone, to try and
maximize compliance.
The primary outcome measure is the ALSFRS-R score obtained monthly for all treated
participants (in person at screening/baseline, month 1, month 3 and month 6; via telephone at
months 2, 4 and 5). We will also obtain this measure by phone at months 6 and 12 of the
extension. For all enrolled PALS in Groups 1 and 2, we will compare the slope of ALSFRS-R
progression before enrollment to the slop of ALSFRS-R progression during the trial. ALSFRS-R
is a quickly administered (five minute) ordinal rating scale (ratings 0-4) used to determine
patients' assessments of their capability and independence in 13 functional activities. All
13 activities are relevant in ALS. Initial validity was established in ALS patients by
documenting that their change in ALSFRS-R scores, which correlated with change in strength
over time, was closely associated with quality of life measures, and predicted survival. The
test-retest reliability is greater than 0.88 for all 13 itemsactivities. The ALSFRS-R
declines linearly with time over a wide range during the course of ALS. The minimum
clinically significant change in this scale is said to be 20%. The measure can be reliably
conducted over the phone.
Secondary outcome measures include:
MR Spectroscopy NAA/Cr ratio in motor cortex will be measured at screening/baseline and 1
month time points. This measure declines over time in patients with ALS. This measure can
respond to treatment; it was shown to improve over 3 weeks in patients with ALS on riluzole
compared to a group that was not on this treatment. We will compare the MR spectroscopy
changes over 1 month in Group 1 to the MR spectroscopy changes over 1 month in Group 2.
A Serum and Urine Biomarker Panel will be obtained at screening/baseline, 1 month and 6-month
time points and analyzed using liquid chromatography/tandem mass spectrometry. Laboratory,
pathologic, and epidemiologic evidence clearly supports the hypothesis that oxidative stress
is central in the ALS pathogenic process, particularly in genetically susceptive individuals.
Oxidative stress biomarkers in cerebrospinal fluid, plasma, and urine are elevated,
suggesting that abnormal oxidative stress is generated outside of the central nervous system.
Magnitude of lipid peroxidation, measured as non-enzymatic oxidation products of arachidonic
acid, F2-isoprostanes, appears the most obvious oxidative stress marker. We will measure
urine F2-isoprostane metabolites (class III: iPF2α-III, and 2,3-dinor iPF-2alpha-III, class
VI: iPF-2alpha-VI, and 8,12-iso-iPF-2alpha-VI), urine creatinine, and serum and urine
glutamate, a-keto-glutarate, NADH, coenzyme A levels in all treated participants and healthy
controls at screening/baseline, month 1 and month 6 time points. We will compare the
biomarker changes at different times points across between Groups 1, 2 and 3.
For safety monitoring:, concomitant medications, vital signs, weight, physical exam and
safety labs (CBC, CMP, Lipid Profile, GGT, LFT and pregnancy testing for sexually active
females with child bearing potential) will be measured at screening/baseline, 1 month, 3
month, and 6-month time points. Adverse events will be monitored continuously throughout the
study, as described in Section 5.1.
The primary statistical analysis is the slope of the revised ALS functional rating scale
(ALSFRS-R) during treatment compared to pre-treatment. Pre-treatment slope for each
participant will be estimated as follows: (48-enrollment ALSFRS-R)/months since symptom
onset. This frequently used "pre-slope" method is simple and inexpensive, and can predict
disease progression as well as more complicated and expensive tools, at least for periods of
less than 1 year.
ALS Clinic. The first 5 enrolled PALS (Group 1) will receive standard ALS care for the first
month, then standard care plus Triheptanoin for the next 5 months. The next 5 enrolled PALS
(Group 2) will receive standard ALS care plus Triheptanoin for 6 months (Figure 1). All Group
1 and Group 2 PALS who complete this 6-month study will have an option for Triheptanoin
treatment extension for an additional 12 months. In addition to the PALS, there will also be
5 healthy controls enrolled (Group 3), people that do not have ALS or any other
neurodegenerative disease). These participants will not receive any treatment; the only
outcome measure they will complete is serum and urine biomarker testing at
screening/baseline, month 1 and month 6.
The rationale for delaying triheptanoin treatment in one group is to look for differences in
MR spectroscopy related to treatment at the 1 month time point. The target triheptanoin dose
for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable
and altered brain MR spectroscopy in patients with Huntington's Disease. Participants will
taper up to this dose as follows: start at 0.25g/kg/d for 1 week, then take 0.5g/kg/d for 1
week, then take 1g/kg/d and stay on this dose for the duration of the study. Triheptanoin
will be administered orally with food or by gastrostomy tube over 3 divided doses (breakfast,
lunch, and dinner). If at any point after week 1 a participant does not appear to be
tolerating their current dose, it will be reduced by 0.25g/kg/d. If they cannot tolerate the
starting dose of 0.25g/kg/d, the treatment will be discontinued. A dietician will make
contact with all participants every month, either in person or by telephone, to try and
maximize compliance.
The primary outcome measure is the ALSFRS-R score obtained monthly for all treated
participants (in person at screening/baseline, month 1, month 3 and month 6; via telephone at
months 2, 4 and 5). We will also obtain this measure by phone at months 6 and 12 of the
extension. For all enrolled PALS in Groups 1 and 2, we will compare the slope of ALSFRS-R
progression before enrollment to the slop of ALSFRS-R progression during the trial. ALSFRS-R
is a quickly administered (five minute) ordinal rating scale (ratings 0-4) used to determine
patients' assessments of their capability and independence in 13 functional activities. All
13 activities are relevant in ALS. Initial validity was established in ALS patients by
documenting that their change in ALSFRS-R scores, which correlated with change in strength
over time, was closely associated with quality of life measures, and predicted survival. The
test-retest reliability is greater than 0.88 for all 13 itemsactivities. The ALSFRS-R
declines linearly with time over a wide range during the course of ALS. The minimum
clinically significant change in this scale is said to be 20%. The measure can be reliably
conducted over the phone.
Secondary outcome measures include:
MR Spectroscopy NAA/Cr ratio in motor cortex will be measured at screening/baseline and 1
month time points. This measure declines over time in patients with ALS. This measure can
respond to treatment; it was shown to improve over 3 weeks in patients with ALS on riluzole
compared to a group that was not on this treatment. We will compare the MR spectroscopy
changes over 1 month in Group 1 to the MR spectroscopy changes over 1 month in Group 2.
A Serum and Urine Biomarker Panel will be obtained at screening/baseline, 1 month and 6-month
time points and analyzed using liquid chromatography/tandem mass spectrometry. Laboratory,
pathologic, and epidemiologic evidence clearly supports the hypothesis that oxidative stress
is central in the ALS pathogenic process, particularly in genetically susceptive individuals.
Oxidative stress biomarkers in cerebrospinal fluid, plasma, and urine are elevated,
suggesting that abnormal oxidative stress is generated outside of the central nervous system.
Magnitude of lipid peroxidation, measured as non-enzymatic oxidation products of arachidonic
acid, F2-isoprostanes, appears the most obvious oxidative stress marker. We will measure
urine F2-isoprostane metabolites (class III: iPF2α-III, and 2,3-dinor iPF-2alpha-III, class
VI: iPF-2alpha-VI, and 8,12-iso-iPF-2alpha-VI), urine creatinine, and serum and urine
glutamate, a-keto-glutarate, NADH, coenzyme A levels in all treated participants and healthy
controls at screening/baseline, month 1 and month 6 time points. We will compare the
biomarker changes at different times points across between Groups 1, 2 and 3.
For safety monitoring:, concomitant medications, vital signs, weight, physical exam and
safety labs (CBC, CMP, Lipid Profile, GGT, LFT and pregnancy testing for sexually active
females with child bearing potential) will be measured at screening/baseline, 1 month, 3
month, and 6-month time points. Adverse events will be monitored continuously throughout the
study, as described in Section 5.1.
The primary statistical analysis is the slope of the revised ALS functional rating scale
(ALSFRS-R) during treatment compared to pre-treatment. Pre-treatment slope for each
participant will be estimated as follows: (48-enrollment ALSFRS-R)/months since symptom
onset. This frequently used "pre-slope" method is simple and inexpensive, and can predict
disease progression as well as more complicated and expensive tools, at least for periods of
less than 1 year.
Inclusion Criteria:
1. Lab supported probable or more definite ALS by El Escorial Criteria
2. Age greater than or equal to 18 years
3. Willing and able to provide informed consent
4. On riluzole at a stable dose for at least 30d or not taking this
5. On Radicava at a stable dose for at least 30d or not taking this
6. Life expectancy at least 6 months
7. Currently managed on a reasonably stable diet, avoidance of fasting, carnitine or
medium chain triglyceride (MCT) oils
8. Must stop any other experimental ALS treatment for at least 30 days prior to screening
9. If sexually active, must agree to use contraceptive or abstinence for duration of
treatment with triheptanoin
10. Females of child bearing age must have negative pregnancy test at screening
Exclusion Criteria:
1. Unwilling or unable to provide informed consent
2. Previous intolerance or adverse reaction to triheptanoin or MCT
3. Conditions that will prohibit MRI scanning (metal in eye, some surgical implants,
claustrophobia, inability to lie supine)
4. Have any other co-morbid conditions that in the opinion of the study investigator,
places the participant at increased risk of complications, interferes with study
participation or compliance, or confounds study objectives
We found this trial at
1
site
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Click here to add this to my saved trials
